CERo Therapeutics Holdings
CERO · NASDAQ
$0.0052−$0.0009 (−14.75%)TodayMarket closed ·
Prev close $0.0061
Key indicators
CERO profitability and balance sheet ratios
Return on equity -4.8% in Jun 2023, down 4.2 points on a year earlier.
| Period | Return on equity |
|---|---|
| Jun 2022 | -0.6% |
| Sep 2022 | -0.4% |
| Dec 2022 | -0.5% |
| Mar 2023 | -0.9% |
| Jun 2023 | -4.8% |
Income statement
Revenue and profit by reporting period
Revenue
Net income
| Line item | Q1 FY25 | Q2 FY25 | Q3 FY25 |
|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M |
| Gross profit | $0.0M | $0.0M | $0.0M |
| Operating income | −$5.0M | −$4.7M | −$4.4M |
| Net income | −$5.5M | −$30.1M | −$11.5M |
| Diluted EPS | -$31.82 | -$61.71 | -$9.10 |
Balance sheet
What the company owns and owes at period end
Total assets
Total liabilities
| Line item | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|
| Total assets | $6.2M | $8.0M | $6.2M |
| Total liabilities | $8.1M | $8.3M | $7.8M |
| Shareholder equity | −$1.9M | −$0.3M | −$1.6M |
| Cash and short-term investments | $3.3M | $5.2M | $3.8M |
| Total debt | $0.0M | $0.0M | $0.0M |
Cash flow
Cash in and out from operations, investing and financing
Operating
Investing
Financing
| Line item | Q1 FY25 | Q2 FY25 | Q3 FY25 |
|---|---|---|---|
| Operating cash flow | −$4.4M | −$4.6M | −$3.2M |
| Investing cash flow | $0.0M | $0.0M | $0.5M |
| Financing cash flow | $6.3M | $2.7M | $1.4M |
| Capital expenditure | $0.0M | $0.0M | $0.0M |
| Free cash flow | −$4.4M | −$4.6M | −$3.2M |
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.